Viewing Study NCT03720457

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 6:44 PM
Ignite Modification Date: 2026-01-04 @ 12:47 PM
Study NCT ID: NCT03720457
Status: UNKNOWN
Last Update Posted: 2021-08-31
First Post: 2018-10-24
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory CD19-positive Lymphoma.
Sponsor: Hrain Biotechnology Co., Ltd.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None CD19-positive View
None Diffuse Large B-cell Lymphoma View
None Follicular Lymphoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None CD19 View
None CAR-T View
None Diffuse Large B-cell Lymphoma View
None Follicular Lymphoma View
None Relapsed /Refractory View